Dyadic International (DYAI) Common Equity (2017 - 2026)
Dyadic International (DYAI) posted Common Equity of -$407732.0 for Q1 2026, down 133.08% sequentially from $1.2 million in Q4 2025, and down 144.15% YoY from $923611.0 in Q1 2025.
Dyadic International (DYAI) Common Equity (2017 - 2026) Analysis & Trends
Dyadic International has reported Common Equity for 10 years, with the latest figure at -$407732.0 in Q1 2026.
- Quarterly Common Equity fell 144.15% year-over-year to -$407732.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$407732.0 (down 144.15% YoY) and the FY2025 annual result came in at $1.2 million, down 50.11% from the prior year.
- Common Equity retreated to -$407732.0 in Q1 2026 per DYAI's latest filing, from $1.2 million in the prior quarter.
- Over five years, Common Equity peaked at $16.4 million in Q1 2022 and troughed at -$529701.0 in Q2 2025.
- A 5-year average of $6.1 million and a median of $4.5 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity declined 23.59% in 2025, then sank 144.15% in 2026.
- Over 5 years, Common Equity stood at $11.1 million in 2022, then tumbled by 46.98% to $5.9 million in 2023, then slumped by 57.98% to $2.5 million in 2024, then sank by 50.11% to $1.2 million in 2025, then slumped by 133.08% to -$407732.0 in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$407732.0, $1.2 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | -407,732.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -407,732.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 2.61 Mn |
| Jun 30, 2025 | -529,701.00 |
| Mar 31, 2025 | 923,611.00 |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.17 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 5.88 Mn |
| Sep 30, 2023 | 7.65 Mn |
| Jun 30, 2023 | 8.99 Mn |
| Mar 31, 2023 | 10.80 Mn |
| Dec 31, 2022 | 11.09 Mn |
| Sep 30, 2022 | 12.61 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | 16.39 Mn |
| Dec 31, 2021 | 18.39 Mn |
| Sep 30, 2021 | 21.90 Mn |
| Jun 30, 2021 | 23.16 Mn |